InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,475.09
(
0.27%
)
US TECH 100
19,196.40
(
-0.42%
)
Dow Jones
39,169.52
(
0.13%
)
Brent Oil
87.03
(
0.58%
)
Bitcoin
62,628.76
(
-0.35%
)
Post# of 252455
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119964
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 61777

Sunday, 05/04/2008 8:46:02 PM

Sunday, May 04, 2008 8:46:02 PM

Post# of 252455
Telaprevir PROVE-1/2 Results Made Simple

The PROVE-1 and PROVE-2 trials had almost mind-boggling complexity because there were so many treatment arms and protocols (#msg-11248731, #msg-28746843). To sift through this complexity, I’ve condensed the data into a form that is simple to understand yet accurate enough for investment purposes.

• The starting point for the calculations below is the set of all PROVE-1/PROVE-2 patients who were treated with 12 weeks of Telaprevir followed by 12 weeks of SoC.

• Deduct the 17% of patients who discontinued treatment due to adverse events or were lost to follow-up, leaving 83% of the initial patients.

• From the above, deduct the 10% of patients who never achieved undetectable virus, leaving 75% of the original patients.

• From the above, deduct the 2% of patents who experienced a viral breakthrough on treatment, leaving 73% of the original patients. These are the patients who had undetectable virus at the end of 24 weeks of treatment.

• From the above, deduct the 11% of patients who relapsed after stopping treatment, leaving 65% of the original patients who had an SVR. This was an improvement of 20 percentage points vs the 45% SVR rate in the PROVE-1/2 SoC 48-week control arms.

(Patients in PROVE-1/2 who did not achieve an RVR [undetectable virus at week 4] stopped Telaprevir and completed a total of 48 weeks of treatment with the remainder of the 48 weeks on SoC. Although a small number of these patients achieved an SVR after 48 weeks of treatment, they are not included in the 65% figure above.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up